WFB Story
Workforce Biologics is an innovative early-stage company comprising health and design professionals with a focus on workplace safety. Their combined experience in infectious disease spans decades and together they have developed a system to enhance workplace bio-security. The molecule at the heart of the covX® system provides virucidal action that is ongoing (residual) over several hours and has independently verified efficacy against COVID-19
Workforce Biologics is proud of the innovation behind covX® and its delivery system. The 3-step system will enhance pandemic protection across workforces, safeguard business continuity, and build confidence across a wide range of organisations and sectors
WFB Team
Dr. Miles Banwell
CEO and Founder
Consultant Plastic & Reconstructive Surgeon. Previous research background in biomedical sciences (PhD, Immunology)
Dr. Paul Clarke
Infectious Diseases Physician
Formerly, Consultant at The London School of Hygiene & Tropical Medicine. Founder of MASTA (Medical Advisory Service for Travellers Abroad)
Michael Messenger
Industrial Designer
Pioneer in global disaster relief shelters & emergency infrastructure. Founder of Aircell Structures Ltd
Nigel Irving
Electronics Engineer
Outstanding career in marine & radio electronics; authority in field of prototype design and system diagnostics
WFB Timeline
-
2003
Original SARS-CoV epidemic in China
-
2004
Dr. Paul Clarke patents active molecule for virucidal action (skin, masks, surfaces)
-
2005
Michael Messenger's first production of inflatable air-frame shelters for use by humanitarian agencies across the world
-
2011
USA patent renews – author Dr. Paul Clarke
-
2017
Dr. Paul Clarke & Dr. Miles Banwell collaborate on anti-microbial use of active molecule in hospital settings in light of emerging threat from antibiotic resistance
-
March, 2020
WHO assigns COVID-19 pandemic status
-
May, 2020
WFB founded as COVID-19 pandemic response
-
July, 2020
DSTL Porton Down published their independent report confirming virucidal action of active molecule against SARS-CoV-2 (COVID-19)
-
Febuary, 2021
Projected first delivery of covX®
-
July, 2021
covX® misting booth in full-time operation for arrivals at Kamuzu International Airport, Malawi